List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Axillary Hyperhidrosis - Overview
Axillary Hyperhidrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics LLC
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Axillary Hyperhidrosis - Drug Profiles
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrronium tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReViVox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sofpironium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Axillary Hyperhidrosis - Dormant Projects
Axillary Hyperhidrosis - Discontinued Products
Axillary Hyperhidrosis - Product Development Milestones
Featured News & Press Releases
Mar 04, 2020: Brickell Biotech announces late-breaking oral presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for sofpironium bromide
Feb 20, 2020: Brickell Biotech announces publication of its U.S. phase 2b study results for Sofpironium Bromide in patients with primary axillary hyperhidrosis in the journal of the American Academy of Dermatology
Jan 10, 2020: Brickell Bio’s development partner, Kaken Pharmaceutical, submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin
Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Axillary Hyperhidrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H1 2020
Axillary Hyperhidrosis - Pipeline by DelNova Inc, H1 2020
Axillary Hyperhidrosis - Pipeline by Dermata Therapeutics LLC, H1 2020
Axillary Hyperhidrosis - Pipeline by Dermavant Sciences Inc, H1 2020
Axillary Hyperhidrosis - Pipeline by Dermira Inc, H1 2020
Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2020
Axillary Hyperhidrosis - Pipeline by Medytox Inc, H1 2020
Axillary Hyperhidrosis - Pipeline by Revance Therapeutics Inc, H1 2020
Axillary Hyperhidrosis - Dormant Projects, H1 2020
Axillary Hyperhidrosis - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Axillary Hyperhidrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• Brickell Biotech Inc
• DelNova Inc
• Dermata Therapeutics LLC
• Dermavant Sciences Inc
• Dermira Inc
• Dr. August Wolff GmbH & Co KG Arzneimittel
• Medytox Inc
• Revance Therapeutics Inc